The risk of death 10 years after diagnosis of Prostate cancer localized is weak regardless of the treatment implemented, depending on the results of a study published in the New England Journal of Medicine. There are no significant differences in outcome between radiotherapy, chemotherapy or active disease surveillance.
Researchers at the University of Oxford in the UK conducted a clinical trial with 1,643 patients aged 50 to 69 to test the effectiveness of treatments for prostate cancer. Participants were randomly selected to undergo surgical removal of the tumor, radiation therapy, or undergo active disease surveillance. This last option consists of regular medical consultations with a prostate exam, biopsies and a PSA (Prostate Specific Antigen) test to measure the level of an antigen that assesses the progress of the disease.
Ten years after prostate cancer diagnosis, little difference between treatments
During the study and 10 after diagnosis, seventeen of the participants died, eight in the monitoring group, five of those who had surgery and four in the radiotherapy group.
The results of this trial showed that at 10 years, mortality from localized prostate cancer is low, regardless of the treatment assigned, with no significant difference between the therapies. Surgery and radiation therapy were associated with a lower incidence of disease progression and metastasis compared to active surveillance, but not really significant.
“This study seems to show that for men with a localized prostate cancer, active surveillance does not present much more danger and avoids the potential harmful effects which could result from the surgery on sexual activity and the intestines ”, judged John Burn, professor of genetics at the University of Newcastle in the United Kingdom , who did not participate in the study.
Read also:
Orgasm Reduces Risk of Prostate Cancer
Colon, breast, prostate: we more survive these three cancers
Prostate cancer: a laser operation to treat the tumor
